Profile data is unavailable for this security.
About the company
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
- Revenue in USD (TTM)218.71m
- Net income in USD-113.70m
- Incorporated2015
- Employees145.00
- LocationIDEAYA Biosciences Inc7000 SHORELINE CT, SUITE 350SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 443-6209
- Fax+1 (302) 655-5049
- Websitehttps://www.ideayabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 9.68m | -222.74m | 2.45bn | 118.00 | -- | 7.72 | -- | 253.17 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.48bn | 624.00 | -- | 11.33 | -- | 8.96 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | 443,871.80 | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -30.92 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.54bn | 155.00 | -- | 3.41 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.61bn | 317.00 | -- | 5.01 | -- | 61.02 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.61bn | 240.00 | -- | 3.33 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Travere Therapeutics Inc | 490.73m | -50.26m | 2.72bn | 497.00 | -- | 23.38 | 259.86 | 5.55 | -0.603 | -0.3293 | 5.30 | 1.26 | 0.8184 | 1.71 | 9.15 | 987,382.30 | -8.38 | -37.69 | -11.99 | -48.59 | 97.89 | 96.60 | -10.24 | -116.71 | 2.70 | -- | 0.7308 | -- | 110.45 | 19.87 | 84.32 | -- | 18.81 | -- |
| Veracyte Inc | 517.15m | 66.35m | 2.86bn | 755.00 | 44.20 | 2.18 | 32.60 | 5.53 | 0.8147 | 0.8147 | 6.45 | 16.50 | 0.3822 | 7.31 | 11.34 | 684,960.30 | 4.90 | -1.69 | 5.17 | -1.78 | 70.10 | 67.87 | 12.83 | -5.22 | 7.81 | -- | 0.00 | -- | 16.01 | 34.50 | 174.89 | -- | 27.81 | -- |
| Vera Therapeutics Inc | 0.00 | -299.62m | 2.88bn | 249.00 | -- | 4.77 | -- | -- | -4.66 | -4.66 | 0.00 | 8.48 | 0.00 | -- | -- | 0.00 | -43.10 | -46.45 | -45.69 | -50.25 | -- | -- | -- | -- | -- | -- | 0.1102 | -- | -- | -- | -96.92 | -- | 44.79 | -- |
| Ideaya Biosciences Inc | 218.71m | -113.70m | 2.90bn | 145.00 | -- | 2.84 | -- | 13.27 | -1.30 | -1.30 | 2.46 | 11.65 | 0.1959 | -- | 73.20 | 1,508,345.00 | -10.18 | -18.78 | -10.68 | -20.00 | -- | -- | -51.99 | -185.86 | -- | -- | 0.00 | -- | 3,024.43 | 62.11 | 58.58 | -- | 36.87 | -- |
| Beam Therapeutics Inc | 139.74m | -79.99m | 2.92bn | 511.00 | -- | 2.36 | -- | 20.91 | -0.9703 | -0.9703 | 1.41 | 12.17 | 0.1081 | -- | -- | 273,469.70 | -6.19 | -19.28 | -6.94 | -22.57 | -- | -- | -57.24 | -176.36 | -- | -- | 0.00 | -- | 120.01 | 466.27 | 78.77 | -- | -1.79 | -- |
| Arcus Biosciences Inc | 247.00m | -353.00m | 3.00bn | 601.00 | -- | 4.75 | -- | 12.15 | -3.30 | -3.30 | 2.30 | 5.04 | 0.2158 | -- | 12.05 | 410,981.70 | -30.84 | -18.85 | -38.54 | -22.29 | -- | -- | -142.92 | -103.61 | -- | -- | 0.1356 | -- | -4.26 | 26.08 | -24.73 | -- | -8.12 | -- |
| Viridian Therapeutics Inc | 70.85m | -342.60m | 3.09bn | 252.00 | -- | 5.22 | -- | 43.64 | -4.00 | -4.00 | 0.8355 | 7.09 | 0.0863 | -- | -- | 281,146.80 | -41.73 | -44.39 | -44.98 | -47.63 | -- | -- | -483.57 | -1,390.51 | -- | -- | 0.1044 | -- | 23,359.93 | 132.18 | -26.91 | -- | 63.78 | -- |
| Edgewise Therapeutics Inc | 0.00 | -167.80m | 3.19bn | 146.00 | -- | 6.04 | -- | -- | -1.63 | -1.63 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -32.29 | -28.13 | -33.96 | -29.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.40 | -- | 4.75 | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.33bn | 503.00 | -- | 3.24 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.34bn | 102.00 | -- | 5.94 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.41bn | 2.90k | -- | 3.37 | -- | 3.75 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
Data as of Mar 02 2026. Currency figures normalised to IDEAYA Biosciences Inc's reporting currency: US Dollar USD
60.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 13.15m | 15.00% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 7.02m | 8.01% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.54m | 7.47% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 5.28m | 6.02% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.36m | 4.97% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.13m | 4.72% |
| Baker Bros. Advisors LPas of 31 Dec 2025 | 3.62m | 4.13% |
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 3.40m | 3.88% |
| Logos Global Management LPas of 31 Dec 2025 | 3.13m | 3.57% |
| Adage Capital Management LPas of 31 Dec 2025 | 2.80m | 3.20% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
